drugset / Trial / NCT00625859

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

NCT00625859

Phase 1 Completed 27 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this research study is to look at concentrations of GSK189075, WELLBUTRIN SR and active metabolic products in blood samples when doses of both drugs are taken by mouth. Doses are either taken alone or together. The results will help to determine if doses of GSK189075 and WELLBUTRIN SR can be safely taken together.

Timeline

Start
2008-01-16
Primary completion
2008-04-10
Completion
2008-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg Oral
Subject remogliflozin etabonate Small molecule 250 mg